Allgenesis Biotherapeutics Overview

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.15M

  • Investors
  • 4

Allgenesis Biotherapeutics General Information

Description

Developer of ophthalmic drugs. The company is focused on novel multi-specific fusion proteins for treating diabetic macular edema and wet-age-related macular degeneration; and small molecule eye drops for dry eye and pterygium diseases.

Contact Information

Website
www.allgenesis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9F.-3, No.760, Sec. 4
  • Bade Rd.,Songshan Dist
  • Taipei
  • Taiwan
+886 02
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 9F.-3, No.760, Sec. 4
  • Bade Rd.,Songshan Dist
  • Taipei
  • Taiwan
+886 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allgenesis Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 01-Sep-2019 $4.15M Completed Clinical Trials - General
5. Early Stage VC 01-Dec-2018 Completed Clinical Trials - General
4. Early Stage VC 01-Dec-2017 Completed Clinical Trials - General
3. Early Stage VC 01-Jan-2016 Completed Clinical Trials - General
2. Early Stage VC 01-Jul-2015 $9.7M $12.2M Completed Startup
1. Seed Round 01-Mar-2014 $2.47M $2.47M Completed Startup
To view Allgenesis Biotherapeutics’s complete valuation and funding history, request access »

Allgenesis Biotherapeutics Patents

  • 67

    Total Documents Applications and Grants

  • Total Patents Families

  • 44

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

Allgenesis Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025233915-A1 Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases Pending 10-May-2024
US-20240374753-A1 Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases Pending 11-May-2023
AU-2022458328-A1 Vegfr fusion protein pharmaceutical composition Active 13-May-2022
AU-2022458328-B2 Vegfr fusion protein pharmaceutical composition Active 13-May-2022
EP-4344433-A1 Vegfr fusion protein pharmaceutical composition Pending 13-May-2022 A61K38/179
To view Allgenesis Biotherapeutics’s complete patent history, request access »

Allgenesis Biotherapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Axil Capital Partners Venture Capital Minority
Global Investment Holdings Venture Capital Minority
H&Q Asia Pacific PE/Buyout Minority
Formosa Laboratories Corporation Minority
To view Allgenesis Biotherapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Allgenesis Biotherapeutics FAQs

  • Where is Allgenesis Biotherapeutics headquartered?

    Allgenesis Biotherapeutics is headquartered in Taipei, Taiwan.

  • What industry is Allgenesis Biotherapeutics in?

    Allgenesis Biotherapeutics’s primary industry is Drug Discovery.

  • Is Allgenesis Biotherapeutics a private or public company?

    Allgenesis Biotherapeutics is a Private company.

  • What is Allgenesis Biotherapeutics’s current revenue?

    The current revenue for Allgenesis Biotherapeutics is .

  • How much funding has Allgenesis Biotherapeutics raised over time?

    Allgenesis Biotherapeutics has raised $29.2M.

  • Who are Allgenesis Biotherapeutics’s investors?

    Axil Capital Partners, Global Investment Holdings, H&Q Asia Pacific, and Formosa Laboratories have invested in Allgenesis Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process